FDA-approved
Heart & blood
Nesiritide
Evidence
FDA approved
Class
B-type natriuretic peptide
KEY TAKEAWAY
Nesiritide is a recombinant version of B-type natriuretic peptide, a 32-amino-acid hormone made by the heart. It was sold as Natrecor. The FDA approved nesiritide (Natrecor) in 2001. Later large trials did not show a clear benefit on death or rehospitalization, and it is now rarely used.
Written by the Veylo editorial team · Updated
November 2026
What it is
B-type natriuretic peptide
Approved for
Acutely decompensated heart failure
Key fact
The FDA approved nesiritide (Natrecor) in 2001. Later large trials did not show a clear benefit on death or rehospitalization, and it is now rarely used.
Route
Intravenous infusion
Evidence strength
FDA approved
Nesiritide is a recombinant version of B-type natriuretic peptide, a 32-amino-acid hormone made by the heart. It was sold as Natrecor.
It relaxes blood vessels and increases salt and water loss, which reduces pressure in the heart.
The FDA approved nesiritide (Natrecor) in 2001. Later large trials did not show a clear benefit on death or rehospitalization, and it is now rarely used.
Acutely decompensated heart failure.
Low blood pressure is the main side effect, and kidney function can worsen.
U.S. FDA prescribing information for Nesiritide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.